Skip to main content
. 2017 Feb 23;8(17):28696–28710. doi: 10.18632/oncotarget.15645

Figure 5. Effects of pharmaceutical inhibition of CDK9 on RNA Pol II phosphorylation and MCL-1 expression.

Figure 5

(A) Cells were treated with CAN508 or Flavopiridol for 4 hours. The phosphorylation of RNA Poll II and the expression of MCL-1 were examined by western blot. (B) Cells were treated with CAN508 or Flavopiridol for 4 hours after pretreatment with or without MG123 for 1 hour. Expression of MCL-1 was then detected by western blot. The band intensity was measured with Photoshop software. The data was normalized with host genes (GAPDH or β-actin) and presented as the relative values to corresponding controls. (C) The mRNA levels of MCL-1 were measured by Q-PCR after treatment of CAN508 (left panel) or Flavopiridol (right panel) for 4 hours at indicated dose. Value are shown as means ± SE of three independent experiments. *represents p-value <0.05 compared to untreated controls. (D). Cells were treated with CAN508 or Flavopiridol for 4 hours. The phosphorylation of RNAPII and the expression of c-MYC and CDK9 were examined by western blot.